Xponance’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $3.26M | Sell |
25,975
-1,307
| -5% | -$164K | 0.03% | 430 |
|
2025
Q1 | $3.02M | Buy |
27,282
+215
| +0.8% | +$23.8K | 0.03% | 422 |
|
2024
Q4 | $3.69M | Buy |
27,067
+1,941
| +8% | +$265K | 0.03% | 383 |
|
2024
Q3 | $2.9M | Sell |
25,126
-102
| -0.4% | -$11.8K | 0.03% | 435 |
|
2024
Q2 | $3.47M | Sell |
25,228
-436
| -2% | -$60K | 0.04% | 376 |
|
2024
Q1 | $3.54M | Buy |
25,664
+4,216
| +20% | +$581K | 0.04% | 370 |
|
2023
Q4 | $2.83M | Sell |
21,448
-936
| -4% | -$123K | 0.03% | 386 |
|
2023
Q3 | $2.52M | Sell |
22,384
-55
| -0.2% | -$6.19K | 0.03% | 396 |
|
2023
Q2 | $2.12M | Sell |
22,439
-279
| -1% | -$26.3K | 0.03% | 458 |
|
2023
Q1 | $2.3M | Buy |
22,718
+386
| +2% | +$39.1K | 0.03% | 427 |
|
2022
Q4 | $2.67M | Buy |
22,332
+1,410
| +7% | +$168K | 0.04% | 376 |
|
2022
Q3 | $2.22M | Buy |
20,922
+57
| +0.3% | +$6.05K | 0.04% | 367 |
|
2022
Q2 | $2.03M | Buy |
20,865
+537
| +3% | +$52.3K | 0.04% | 369 |
|
2022
Q1 | $1.91M | Sell |
20,328
-92
| -0.5% | -$8.63K | 0.03% | 385 |
|
2021
Q4 | $1.74M | Sell |
20,420
-36
| -0.2% | -$3.07K | 0.03% | 420 |
|
2021
Q3 | $1.96M | Sell |
20,456
-159
| -0.8% | -$15.3K | 0.04% | 353 |
|
2021
Q2 | $2.01M | Buy |
20,615
+1,146
| +6% | +$112K | 0.04% | 372 |
|
2021
Q1 | $1.89M | Buy |
19,469
+9,938
| +104% | +$966K | 0.04% | 325 |
|
2020
Q4 | $914K | Sell |
9,531
-96
| -1% | -$9.21K | 0.02% | 489 |
|
2020
Q3 | $926K | Buy |
9,627
+94
| +1% | +$9.04K | 0.02% | 437 |
|
2020
Q2 | $1.16M | Buy |
+9,533
| New | +$1.16M | 0.03% | 356 |
|